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Objective: Current understanding of the prognostic impact of depression on mortality after heart 
transplantation (HTx) is limited. We examined whether depression after HTx is a predictor of 
mortality during extended follow-up. Subsequently, we explored whether different symptom 
dimensions of depression could be identified, and whether they were differentially associated 
with mortality. 
Methods: Survival analyses were performed in a sample of 141 HTx recipients assessed for 
depression, measured by self-report of depressive symptoms (Beck Depression Inventory – 
version 1A (BDI-1A)), at median 5.0 years after HTx, and followed thereafter for survival status 
for up to 18.6 years. We used uni- and multivariate Cox proportional hazard models to examine 
the association of clinically significant depression (BDI-1A total score ≥10), as well as the 
cognitive-affective and the somatic subscales of the BDI-1A (resulting from principal component 
analysis) with mortality. In the multivariate analyses, we adjusted for relevant sociodemographic 
and clinical variables. 
Results: Clinically significant depression was a significant predictor of mortality (hazard ratio 
(HR): 2.088; 95% confidence interval (95% CI): 1.366–3.192; p=.001). Clinically significant 
depression also was an independent predictor of mortality in the multivariate analysis (HR: 
1.982; 95% CI: 1.220–3.217; p=.006). The somatic subscale, but not the cognitive-affective 
subscale, was significantly associated with increased mortality in univariate analyses, while 
neither of the two subscales was an independent predictor of mortality in the multivariate 
analysis. 
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Conclusions: Depression measured by self-report after HTx is associated with increased 
mortality during extended follow-up.  Clinical utility and predictive validity of specific 
depression components require further study. 
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Improvements in immunosuppressive therapy and management of somatic complications after 
heart transplantation (HTx) have led to improved survival (1). To enhance outcomes further, 
research has increasingly focused on potentially related psychosocial issues (2, 3), including 
posttransplant depression. 
Although data on the association of depression with increased mortality after HTx seem robust in 
the medium term (i.e., median observation time of 5.4 years across studies in a meta-analysis (4)) 
(4-6), knowledge is limited about depression’s long-term effects on mortality (7). 
Furthermore, several aspects of the interplay between depression and prognosis remain unknown 
or poorly understood. In the setting of coronary artery disease (CAD), an integrative model of the 
complex interplay between depression and prognosis has been proposed (8). Within this 
framework, it is hypothesized that acute depression after acute coronary syndrome (ACS) reflects 
the psychological impact of this event (8). Persistent/recurrent depression is hypothesized to act 
as an indirect causal factor in the progression of CAD via behavioural pathways such as non-
adherence to medication, poor diet, and limited physical activity (8). The model is based partly 
on findings of cognitive-affective and somatic symptom dimensions of depression in depressed 
CAD and ACS patients, with the somatic dimension hypothesized to be associated with less 
favourable prognosis (8). A meta-analysis has confirmed the stronger and more consistent 
association of the somatic (e.g., work difficulty, insomnia, fatigability) than the cognitive-
affective (e.g., sense of failure, guilt, self-dislike) symptom dimension with cardiovascular 
prognosis (including all-cause mortality), based on 13 prospective longitudinal studies in patients 
with heart disease (9); however we lack comparable data on HTx samples. 
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Several sociodemographic and clinical characteristics are associated with increased mortality 
after HTx. Studies focusing on the interplay between depression and prognosis should therefore 
include these variables as covariates. Recipient age (1), recipient sex (1), reason for HTx (10), 
donor age (1), and allograft ischemic time (1) have been directly associated with increased 
mortality after HTx. Hypertension, hyperlipidemia, renal dysfunction, diabetes, and cardiac 
allograft vasculopathy (CAV) are important morbidities after HTx, with renal dysfunction and 
CAV being among the most important contributors to mortality (1). Posttransplant smoking is 
associated with increased mortality in solid organ transplant recipients, including HTx recipients 
(11). Regarding body mass index (BMI), data from samples of HTx recipients are somewhat 
conflicting (10, 12, 13). BMI should nevertheless be included as covariate in survival analyses 
because BMI values in the range indicating overweight and obesity are associated with increased 
mortality in never-smokers without chronic diseases (14). 
 
In this study, we aimed to extend existing knowledge about the prognostic impact of depression 
after HTx on mortality. To this end, we examined whether depression, measured by self-report of 
depressive symptoms, at a median of 5.0 years (interquartile range (IQR): 2.1–8.4) after HTx 
predicted subsequent mortality during extended follow-up (i.e., up to 18.6 years). In subsequent 
analyses, we explored whether cognitive-affective and somatic symptom dimensions of 
depression could be identified in our sample of HTx recipients and, in that case, whether these 
two symptom dimensions were differentially associated with mortality. In multivariate analyses, 
we adjusted for relevant sociodemographic and clinical variables. 





In Norway, all HTx surgery is performed at the national transplant centre located at Oslo 
University Hospital (OUH). Selection of HTx candidates follows international guidelines (15). 
After the first year, HTx recipients return annually to OUH for their follow-up assessments. Of 
220 HTx recipients who returned to OUH for their annual follow-up between 1998 and 2000, 147 
were included in a study focused on psychiatric symptoms and quality of life. Cross-sectional 
data (16), longitudinal data on the association between depressive symptoms and mortality during 
a mean follow-up of 6 years (5), and longitudinal data on the association between self-reported 
physical function and mortality during a mean follow-up of 10 years (17) have been reported 
earlier. For the present study, end of follow-up for survival status was June 16, 2017. Of the 147 
included HTx recipients from the original cohort, 6 were excluded from the current analyses 
because they had insufficient data for calculating a total score of the Beck Depression Inventory – 
version 1A (BDI-1A) (18). Thus, we present data on 141 participants. By June 16, 2017, 100 of 
these 141 HTx recipients had died, 2 were re-transplanted, and 39 were still alive with the same 
graft (i.e., alive and not re-transplanted). Median follow-up interval from inclusion in the main 
study and end of follow-up for the present study was 10.7 years (IQR: 5.8–17.6; mean: 10.9; 
standard deviation (SD): 5.8). Maximum of follow-up was 18.6 years. Median time interval 
between HTx and inclusion into the main study (i.e., self-report of depressive symptoms) was 5.0 
years (IQR: 2.1–8.4; mean: 5.6; SD: 3.9). 
Procedures 
The present study is a secondary analysis. To this end, the database of the main study was 
updated regarding survival status and cause of death through June 16, 2017. The regional 
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committee for medical and health research ethics had approved the present secondary analysis as 
part of the approval of the main study. 
Measures 
Self-report of depressive symptoms 
Depressive symptoms were measured by self-report at time of inclusion (i.e., 1998–2000), at a 
median of 5.0 years (IQR: 2.1–8.4) after HTx, with the BDI-1A (18). The BDI-1A consists of 21 
items, rated from 0 to 3 in terms of intensity (19). The total score is the sum of the scores of the 
single items (range: 0–63). A Cronbach’s alpha of .862 in the present sample indicates good 
internal consistency for the total score of the BDI-1A. Standard cut-off points to identify severity 
of depressive symptoms have been determined by the developers of the scale (19). A total score 
of 10 or higher indicates clinically significant depression (19); a total score between 10 and 18 
indicates mild depression and a total score of 19 or higher indicates moderate or severe 
depression (19). A BDI-1A total score ≥10 resulted in a sensitivity of 81.8% and a specificity of 
78.7% to detect major depression in a sample of 199 CAD patients (20). 
Sociodemographic and clinical characteristics 
Sociodemographic and clinical characteristics from time of HTx and time of inclusion were 
analysed to describe the sample, including the covariates in the multivariate survival analyses 
(see below). Specifically, we report recipient age at time of inclusion (in years), recipient sex, 
time between HTx and inclusion (in years), reason for HTx, donor age (in years), cold ischemic 
time (in minutes), renal function at time of inclusion, presence of CAV at time of inclusion, 
smoking status at time of inclusion (yes/no), and BMI at time of inclusion (in kg/m2). Reason for 
HTx was classified into three categories: non-ischemic cardiomyopathy (defined according to the 
American Heart Association (21)), ischemic cardiomyopathy, or other. Renal function was 
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measured by means of estimated glomerular filtration rate (eGFR) (5, 22), and renal dysfunction 
defined as eGFR <60 ml/min/1.73 m2. CAV was defined as luminal narrowing in one or more of 
the main arteries based on the presence of any of the following: any degree of stenosis, distal 
tapering/pruning, or loss of tertiary vessels (5). Smoking status was based on self-report, nurses’ 
report, or hospital medical records (5). Cause of death is reported as part of the description of the 
sample. 
Statistical analysis 
Descriptive data are presented as frequencies and proportions or means and SD, as appropriate. 
Because mortality was the event of interest, re-transplanted participants were censored at the time 
of re-HTx in the survival analyses. Observation time started at time of inclusion in the main study 
(i.e., 1998–2000) and was measured in days until death or censoring (i.e., end of follow-up or re-
HTx) as appropriate. No participant was lost to follow-up regarding survival status. 
We used the Kaplan-Meier method to calculate survival curves and tested for differences in 
survival with the log-rank test between those with and without depression (i.e., BDI-1A total 
score ≥10 and <10) at time of inclusion. 
Predictive validity of depression (i.e., BDI-1A total score ≥10), as well as the relevant covariates 
(see below) on mortality, was assessed with univariate Cox proportional hazard models. For the 
categorical variables, the category associated with lower risk for mortality was chosen as the 
reference category. Furthermore, we calculated a multivariate Cox proportional hazard model, 
considering depression and the covariates. For the presented Cox proportional hazard models, 
hazard ratios (HRs), 95% confidence intervals (95% CIs), and corresponding p-values are 
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reported. The multivariate model is based on data for all participants with complete datasets, thus 
incorporating data for 136 out of 141 participants. 
For the reasons outlined in the introduction, the following variables were included as covariates 
in the multivariate analysis: recipient age at time of inclusion, recipient sex, reason for HTx, 
donor age, duration of cold ischemic time, presence of renal dysfunction at time of inclusion, 
presence of CAV at time of inclusion, smoking status at time of inclusion, and BMI at time of 
inclusion. In addition to these variables, we included time between HTx and inclusion as 
covariate because this time interval varied considerably across included participants (median: 5.0 
years; IQR: 2.1–8.4). 
Based on existing literature, indicating that only clinically significant depression (according to 
diagnostic criteria or scores above threshold for caseness on self-report scales) is consistently 
associated with increased mortality (4), and aiming at highest possible applicability of our results 
to the clinic, we used the BDI-1A as dichotomous variable (i.e., BDI-1A total score ≥10 or <10) 
in our primary analyses. However, to explore the possibility of a dose-response relationship, we 
also conducted the analyses with the BDI-1A total score as continuous variable. 
To explore whether cognitive-affective and somatic symptom dimensions of depression could be 
identified in our sample of HTx recipients, we conducted principal component analysis (PCA) on 
the items of the BDI-1A and pre-specified a solution with two components, using oblique rotation 
(Oblimin with Kaiser Normalization). Prior to performance of PCA, the suitability of the data for 
this statistical procedure was assessed. Inspection of the correlation matrix, as well as a Kaiser-
Meyer-Olkin value of .803 and the result of the Bartlett’s test of sphericity (p<.001), indicated 
suitability (23). To assess whether the resulting two components were differentially associated 
with mortality, we created subscales of the BDI-1A, namely a cognitive-affective and a somatic 
This is a non-final version of an article published in final form in Psychosom Med. Jul/Aug 2019;81(6):513-520. doi: 
10.1097/PSY.0000000000000702. https://journals.lww.com/psychosomaticmedicine/pages/default.aspx. 
9 
subscale. To this end, we assigned the 21 single items of the BDI-1A to either the cognitive-
affective or the somatic subscale, based on the loadings from the pattern matrix, and calculated 
sum scores for the subscales, comparable to the total score. As a measure of internal consistency, 
we calculated Cronbach’s alpha for these two subscales. 
In parallel with the abovementioned, we calculated uni- and multivariate Cox proportional hazard 
models with the resulting two subscales of the BDI-1A. In the multivariate Cox proportional 
hazard model, we considered the two subscales of the BDI-1A simultaneously. The subscales of 
the BDI-1A were treated as continuous variables because no cut-offs have been established. 
Level of significance was set to p≤.050 in all analyses. 
Statistical analyses were performed with IBM SPSS Statistics software (IBM Corporation, 
Armonk, NY, USA). 
Results 
Sample characteristics 
At time of inclusion, mean age was 53.5 years, 20.6% were female, and 38.3% had been 
transplanted for non-ischemic cardiomyopathy. Of 141 participants, 36 (25.5%) had a BDI-1A 
total score of 10 or higher, indicative of clinically significant depression. Of these 36 participants, 
24 had a BDI-1A total score between 10 and <19 (i.e., indicative of mild depression), and 12 had 
a BDI-1A total score of 19 or higher (i.e., indicative of moderate or severe depression). More 
details concerning sociodemographic and clinical characteristics are shown in Table 1. During 
follow-up, 100 (70.9%) of the 141 participants died. Cancer (30.0%), CAV (17.0%), and 
infection (12.0%) were the most frequently registered causes of death, while sudden death 
(7.0%), renal dysfunction (5.0%), acute rejection (4.0%), and myocardial infarction (1.0%) were 
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less frequently registered. Other miscellaneous causes of death were listed for 21.0%. Cause of 
death was unknown for 3.0%. No participant received left ventricular assist device as rescue 
therapy in our cohort. 
Survival analyses 
Figure 1 illustrates the course of survival for participants with and without clinically significant 
depression (i.e., BDI-1A total score ≥10 or <10). Log-rank test indicated increased mortality for 
those with clinically significant depression at inclusion compared to those without (χ2: 12.079; df: 
1; p=.001). 
Results from the univariate Cox proportional hazard models are shown in Table 2. In these 
analyses, clinically significant depression (i.e., BDI-1A total score ≥10) was a significant 
predictor of mortality. Clinically significant depression remained an independent predictor of 
mortality in the multivariate analysis. For more details, including HR and 95% CI values, see 
Table 3. 
Treating BDI-1A total score as continuous variable resulted in comparable findings. The BDI-1A 
total score was significantly associated with increased mortality in the univariate Cox 
proportional hazard model (HR: 1.032; 95% CI: 1.006–1.058; p=.016). It also remained an 
independent predictor of mortality in the multivariate analysis (HR: 1.032; 95% CI: 1.002–1.064; 
p=0.039). 
Cognitive-affective and somatic symptom dimensions of depression and their association with 
mortality 
The two-component solution of the PCA explained 40.6% of the variance. The components were 
interrelated (r=.362). After Oblimin rotation, items such as self-dislike, sense of failure, self-
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punishment, sadness, and self-accusation loaded highest on component 1, while items such as 
fatigability, insomnia, loss of libido, and work difficulty loaded highest on component 2. 
Component 1 was labelled the cognitive-affective and component 2 was labelled the somatic 
symptom dimension of depression. Based on the pattern matrix (see Table S1 in the 
Supplemental Digital Content, which depicts the pattern and structure matrix for the PCA with 
Oblimin rotation of the two-component solution of the BDI-1A items), cognitive-affective and 
somatic subscales of the BDI-1A were established for the subsequent survival analyses, as 
outlined earlier. The cognitive-affective subscale consisted of the BDI-1A items 1, 2, 3, 5, 6, 7, 8, 
9, 10, 11, 12, 13, 14, 19, and 20, while the somatic subscale consisted of the BDI-1A items 4, 15, 
16, 17, 18, and 21. Cronbach’s alpha for the cognitive-affective subscale was .850, while it was 
.700 for the somatic subscale. 
In univariate Cox proportional hazard models, the somatic subscale of the BDI-1A was 
significantly associated with increased mortality (HR: 1.191; 95% CI: 1.109–1.280; p<.001), 
while the cognitive-affective subscale of the BDI-1A was not significantly associated with 
mortality (HR: 1.017; 95% CI: .979–1.056; p=0.40). Neither the cognitive-affective nor the 
somatic subscale of the BDI-1A was independently associated with increased mortality in the 
multivariate analysis. More details, including HR and 95% CI values, are shown in Table 4. 
Discussion 
In the present study, we aimed to extend existing knowledge about the prognostic impact of 
depression after HTx on mortality. Clinically significant depression assessed at a median of 5.0 
years after HTx, and defined as a score above threshold on a self-report scale of depressive 
symptoms (i.e., BDI-1A total score ≥10), was associated with increased mortality during 
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extended follow-up (i.e., up to 18.6 years), even after adjustment for relevant sociodemographic 
and clinical variables. 
Subsequent exploratory analyses suggested that a cognitive-affective and a somatic symptom 
dimension of depression might exist in our sample of HTx recipients. While the somatic 
symptom dimension was associated with mortality in univariate analysis, neither the cognitive-
affective nor the somatic symptom dimension was independently associated with mortality in 
multivariate analysis. 
 
Our results confirm earlier reports on the association of depression with increased mortality (4-6) 
after HTx. At the same time, our results extend previous limited knowledge about depression’s 
long-term effects on mortality. Only one earlier report examined the relationship between 
depression and survival during extended follow-up (i.e., mean follow-up: 7.8 years) (7). Among 
107 HTx recipients, assessed with regard to depression by a clinician one to five years after HTx, 
depression was not associated with mortality, while age at HTx, cancer, and low adherence were 
(7). The discrepancy in findings might be due to inclusion of different covariates, differences in 
analytical techniques, and/or different methods for assessing depression. Our results are however, 
in line with results from a meta-analysis, considering studies with primarily shorter follow-up 
intervals (4). 
Our results also suggest that a dose-response relationship between self-reported depressive 
symptoms after HTx and mortality might exist. Earlier reports on HTx samples were inconclusive 
in this regard (6, 24). However, existence of a dose-response relationship would be in accordance 
with data on patients with CAD (25, 26). 
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We are not aware of any earlier report concerning different symptom dimensions of depression in 
HTx recipients. Thus, it is difficult to relate our exploratory results to truly comparable data, 
having in mind, that HTx recipients differ substantially from all other patients with heart disease 
(e.g., use of necessary immunosuppressive medication). However, our finding that a cognitive-
affective and a somatic symptom dimension of depression might exist is consistent with data on 
patients with heart disease (9). However, a differential prognostic impact on mortality, as 
reported for samples of patients with heart disease (9), could not be demonstrated. 
 
The following aspects need consideration in the interpretation of our main result. First, we 
defined clinically significant depression based on a score above threshold on a self-report scale of 
depressive symptoms (i.e., BDI-1A total score ≥10). While BDI-1A is an accepted measure and 
has been widely used in research on depression in somatic disease samples (included heart 
disease samples) (27), the methodological limitations of BDI-1A’s use as measure of clinically 
significant depression have been discussed in the literature, including the possible inflation of 
scale scores due to somatic symptoms of the underlying somatic disease (28). In other words, 
without concurrent clinical diagnostic data, we cannot determine to which extent different 
factors, such as fatigue, psychiatric comorbidities (e.g., anxiety disorder), and/or somatic 
symptoms due to underlying somatic disease or somatic comorbidities might have influenced on 
our participants’ self-report of depressive symptoms. Second, the participants were included at a 
median of 5.0 years after HTx. Thus, the results of our study are not necessarily generalizable to 
other cohorts of HTx recipients, especially those studied earlier after HTx. Third, numerous 
factors are associated with mortality after HTx, making it difficult to account for all potentially 
relevant confounding factors in the same study. Due to the extended follow-up period, we 
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focused on HTx specific factors, included HTx specific morbidities. However, there are other 
variables, which we ideally should have accounted for, such as socioeconomic status and a global 
measure of comorbidity (such as the Charlson comorbidity index). Fourth, depression is a 
complex syndrome. Several factors, that might be involved in the aetiology of depression or 
might be a result of depression (and hence mediators of any linkage between depression and 
mortality), were not assessed in our study. These include biological markers of changes in the 
hypothalamic-pituitary-adrenal axis (e.g., cortisol) and inflammation (e.g., C-reactive protein), as 
well as behavioural factors (e.g., physical inactivity, poor adherence to the medical regimen) (4, 
8, 29, 30). Especially, the interplay between depressive symptoms/depression and physical 
function requires further exploration because both impaired self-reported physical health and 
peak oxygen uptake (an objective marker of cardiopulmonary fitness) have been associated with 
increased mortality (17). A better understanding of this interplay also would be of substantial 
interest regarding the hypothesis that persistent/recurrent depression may exert its negative 
prognostic impact via behavioural pathways (8). 
 
Our study has several additional limitations. First, while we know that no participant was 
receiving treatment for depression at time of inclusion (5), we have no information about the 
longitudinal course of the included participants’ depressive symptoms and/or whether they 
received treatment for depression at a later time point. It might seem surprising that no participant 
was receiving treatment for depression at time of inclusion (i.e., 1998-2000). However, at that 
time, depression screening was not done routinely in conjunction with annual follow-up 
assessments and a psychiatrist was only involved upon request. Thus, against the background of 
the widely accepted notion, that depressed patients not always are recognized as depressed by 
This is a non-final version of an article published in final form in Psychosom Med. Jul/Aug 2019;81(6):513-520. doi: 
10.1097/PSY.0000000000000702. https://journals.lww.com/psychosomaticmedicine/pages/default.aspx. 
15 
their treating non-psychiatric physicians (31), depressed participants might have remained 
undetected and untreated. Moreover, repeated longitudinal assessment of depressive symptoms 
and information about treatment for depression after inclusion would have been of interest 
because persistent/recurrent depression might be associated with less favourable prognosis than 
brief episodes of depression (8, 32, 33). Second, the included participants’ self-report of 
depressive symptoms was gathered at different time points after their HTx (i.e., time between 
HTx and inclusion/self-report of depressive symptoms varied considerably). However, to account 
for this limitation time between HTx and inclusion was included as covariate in the multivariate 
analyses. It is also noteworthy, that the correlation of time between HTx and inclusion and BDI-
1A total score was small and not statistically significant (r=.103; p=.23). Third, several 
limitations pertain to the subsequent exploratory analyses. Even if Cronbach’s alpha for the BDI-
1A cognitive-affective and somatic subscales indicates good to acceptable internal consistency, 
detailed inspection of the pattern matrix resulting from the two-component solution of the PCA 
indicates that assignment of some of the items to one of the two subscales is not clear-cut (see 
Table S1 in the Supplemental Digital Content). However, the pattern in which the single items of 
the BDI-1A loaded highest on either component 1 (labelled the cognitive-affective symptom 
dimension of depression) or component 2 (labelled the somatic symptom dimension of 
depression) was broadly consistent with the results from a meta-analysis on studies in patients 
with heart disease (9). Thus, even though the two-component solution of the PCA presented here 
is broadly consistent with results from a meta-analysis on studies in patients with heart disease 
(9), it does not represent an ideal solution and must be replicated in other samples of HTx 
recipients before firm conclusions can be drawn. Another limitation concerning the PCA is the 
relatively small sample size, compromising the generalizability of the results. However, the 
sample size (n=141) is above the minimum recommended by some authors (i.e., at least 5 cases 
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per analysed item) (23). Furthermore, elevation of scale scores due to symptoms of underlying 
somatic disease (28) have to be discussed in this context as well. If scores on the resulting 
somatic subscale of the BDI-1A were elevated due to somatic symptoms, originating from 
somatic comorbidity in our HTx recipients, lack of adjustment for a global measure of 
comorbidity in our survival analyses would be problematic. The fact that the somatic subscale of 
the BDI-1A was associated with increased mortality only in univariate analysis, might support 
this view. On the other hand, lack of power to detect such an effect in the multivariate analysis 
must be considered as well. Again, concurrent clinical diagnostic data, including description of 
clinical subtypes of depression, would have been useful for interpreting the results of our 
exploratory analyses. 
 
In conclusion, our findings both confirm and extend earlier reports, indicating that clinically 
significant depression after HTx, defined as score above threshold on a self-report scale of 
depressive symptoms, is associated with increased mortality during extended follow-up, even 
after adjustment for relevant sociodemographic and clinical variables. Furthermore, our findings 
suggest that different symptom dimensions of depression may exist. Their clinical utility and 
prognostic validity remains, however, unsettled and should be studied further in order to increase 
our understanding of the complex interplay between depression and prognosis after HTx. 
Increased understanding of this interplay could pave the way for better (i.e., more specific) 
strategies for clinical interventions. 
Adequately powered studies are needed to assess if successful treatment for depression (by means 
of both psychotropic medications and/or psychotherapeutic interventions as appropriate) 
improves survival among HTx recipients. HTx recipients who screen positive for possible 
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clinically significant depression during routine follow-up should in any case be referred to 
specialized diagnostics and treatment because depression negatively affects quality of life and 
function in daily life. 
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Table 1. Sociodemographic and clinical characteristics (n=141) 
Recipient agea (years), mean (SD) 53.5 (12.5) 
Recipient sex, female/male (% female) 29/112 (20.6) 
Time between HTx and inclusion (years), mean (SD) 5.6 (3.9) 
Reason for HTx, n (%)   
Non-ischemic cardiomyopathy 54 (38.3) 
Ischemic cardiomyopathy 73 (51.8) 
Other 14 (9.9) 
Donor age (years), mean (SD) [n=138] 30.9 (11.5) 
Cold ischemic time (min), mean (SD) [n=138] 136 (65) 
eGFRa,b (ml/min/1.73 m2), mean (SD) [n=137] 60.7 (17.6) 
CAVa, n (%) 33 (23.4) 
Smoking statusa, yes/no (% yes) 31/110 (22.0) 
BMIa (kg/m2), mean (SD) [n=140] 26.2 (4.2) 
BDI-1A total scorea,c, mean (SD) 7.4 (6.7) 
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BDI-1A = Beck Depression Inventory – version 1A; BMI = body mass index; CAV = cardiac allograft vasculopathy; eGFR = 
estimated glomerular filtration rate; HTx = heart transplantation; SD = standard deviation. 
aAt time of inclusion. b50.4% had an eGFR <60 ml/min/1.73 m2. c25.5% had a BDI-1A total score ≥10. 
 
  




Table 2. Univariate Cox proportional hazard models (n=141) 
 Reference category (categorical 
variables) 
HR 95% CI p 
Depressiona,b No depression 2.088 1.366 3.192 .001 
Recipient agea (years)  1.074 1.049 1.099 <.001 
Recipient sex Female 1.108 .672 1.826 .70 
Reason for HTx Non-ischemic cardiomyopathy    <.001 
Ischemic cardiomyopathy  2.793 1.766 4.417 <.001 
Other  1.930 .954 3.903 .067 
Donor age (years) [n=138]  1.001 .983 1.018 .94 
Cold ischemic time (min) [n=138]  1.001 .998 1.004 .55 
Renal dysfunctiona,c [n=137] No renal dysfunction 2.529 1.673 3.824 <.001 
CAVa No CAV 3.357 2.154 5.233 <.001 
Smoking statusa,d No smoking 1.413 .892 2.237 .14 
BMIa (kg/m2) [n=140]  1.095 1.051 1.141 <.001 
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Time between HTx and inclusion 
(years) 
 1.071 1.023 1.120 .003 
BDI-1A = Beck Depression Inventory – version 1A; BMI = body mass index; CAV = cardiac allograft vasculopathy; eGFR = 
estimated glomerular filtration rate; HR = hazard ratio; HTx = heart transplantation; 95% CI = 95% confidence interval. 
aAt time of inclusion. bDepression defined as BDI-1A total score ≥10. cRenal dysfunction defined as eGFR <60 ml/min/1.73 m2. 
dYes or no. 
 
  




Table 3. Multivariate Cox proportional hazard model – depression (n=136) 
 Reference category (categorical variables) HR 95% CI p 
Depressiona,b No depression 1.982 1.220 3.217 .006 
Recipient agea (years)  1.057 1.026 1.088 <.001 
Recipient sex Female .914 .492 1.700 .78 
Reason for HTx Non-ischemic cardiomyopathy    .019 
Ischemic cardiomyopathy  2.061 1.198 3.546 .009 
Other  2.518 1.069 5.782 .030 
Donor age (years)  1.020 .997 1.043 .097 
Cold ischemic time (min)  1.000 .996 1.003 .87 
Renal dysfunctiona,c No renal dysfunction 2.036 1.279 3.241 .003 
CAVa No CAV 2.832 1.510 5.310 .001 
Smoking statusa,d No smoking 1.040 .556 1.946 .90 
BMIa (kg/m2)  1.069 1.017 1.124 .008 
Time between HTx and inclusion (years)  1.064 .993 1.139 .078 
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BMI = body mass index; CAV = cardiac allograft vasculopathy; eGFR = estimated glomerular filtration rate; HR = hazard ratio; 
HTx = heart transplantation; 95% CI = 95% confidence interval. 
aAt time of inclusion. bDepression defined as Beck Depression Inventory – version 1A total score ≥10. cRenal dysfunction defined as 
eGFR <60 ml/min/1.73 m2. dYes or no. 
 
  




Table 4. Multivariate Cox proportional hazard model – cognitive-affective and somatic symptom dimension of depression (n=136) 
 Reference category (categorical 
variables) 
HR 95% CI p 
BDI-1A cognitive-affective subscale (resulting 
from PCA)a 
 1.007 .953 1.063 .081 
BDI-1A somatic subscale (resulting from 
PCA)a 
 1.094 .983 1.218 .10 
Recipient agea (years)  1.055 1.024 1.086 <.001 
Recipient sex Female .911 .488 1.702 .77 
Reason for HTx Non-ischemic cardiomyopathy    .029 
Ischemic cardiomyopathy  1.937 1.116 3.362 .019 
Other  2.527 1.101 5.799 .029 
Donor age (years)  1.022 .999 1.045 .066 
Cold ischemic time (min)  1.000 .997 1.004 .81 
Renal dysfunctiona,b No renal dysfunction 1.926 1.198 3.095 .007 
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CAVa No CAV 2.453 1.311 4.592 .005 
Smoking statusa,c No smoking 1.138 .612 2.118 .683 
BMIa (kg/m2)  1.078 1.027 1.133 .003 
Time between HTx and inclusion (years)  1.067 .996 1.142 .064 
BDI-1A = Beck Depression Inventory – version 1A; BMI = body mass index; CAV = cardiac allograft vasculopathy; eGFR = 
estimated glomerular filtration rate; HR = hazard ratio; HTx = heart transplantation; PCA = principal component analysis; 95% CI = 
95% confidence interval. 
aAt time of inclusion. bRenal dysfunction defined as eGFR <60 ml/min/1.73 m2. cYes or no. 
 
  






Figure 1. Survival curves – Kaplan-Meier method 
Depression, defined as BDI-1A total score ≥10. 
BDI-1A = Beck Depression Inventory – version 1A. 
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